Bavarian Nordic A/S/€BAVA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Bavarian Nordic A/S
Bavarian Nordic A/S is a biotechnology company based in Denmark, primarily focused on the development, manufacture, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company's product portfolio includes vaccines for smallpox, Ebola, and other infectious diseases, with its most notable products being the smallpox and monkeypox vaccine, Jynneos (also known as Imvanex or Imvamune). Founded in 1994, Bavarian Nordic has established partnerships with several government agencies, enhancing its strategic positioning in the vaccine development sector. The company operates globally, with its headquarters located in Kvistgaard, Denmark, and manufacturing facilities in various locations supporting its international distribution efforts. Bavarian Nordic leverages proprietary vaccine platform technologies such as MVA-BN, contributing to its competitive advantage in the biotechnology industry.
Ticker
€BAVA
Sector
Primary listing
XGAT
Employees
1,667
Headquarters
Hellerup, Denmark
Website
BAVA Metrics
BasicAdvanced
€2.5B
12.91
€2.41
1.08
-
Price and volume
Market cap
€2.5B
Beta
1.08
52-week high
€34.18
52-week low
€16.50
Average daily volume
9.7K
Financial strength
Current ratio
3.345
Quick ratio
1.584
Long term debt to equity
0.78
Total debt to equity
1.129
Interest coverage (TTM)
313.23%
Profitability
EBITDA (TTM)
287.835
Gross margin (TTM)
53.10%
Net profit margin (TTM)
22.04%
Operating margin (TTM)
24.03%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
€518,500
Management effectiveness
Return on assets (TTM)
6.88%
Return on equity (TTM)
12.65%
Valuation
Price to earnings (TTM)
12.914
Price to revenue (TTM)
2.835
Price to book
1.51
Price to tangible book (TTM)
3.08
Price to free cash flow (TTM)
-42.196
Free cash flow yield (TTM)
-2.37%
Free cash flow per share (TTM)
-0.737
Growth
Revenue change (TTM)
6.13%
Earnings per share change (TTM)
98.24%
3-year revenue growth (CAGR)
51.69%
10-year revenue growth (CAGR)
16.60%
3-year earnings per share growth (CAGR)
20.66%
10-year earnings per share growth (CAGR)
10.32%
Bulls say / Bears say
The US FDA approved a freeze-dried formulation of Jynneos in March 2025, enhancing vaccine shelf life, transportation, and stockpiling logistics and paving the way for expanded government orders (Reuters).
Bavarian Nordic beat second-quarter revenue expectations with DKK 1.65 billion versus a DKK 1.46 billion consensus, driven by strong Travel Health and Public Preparedness demand, underscoring robust commercial execution ahead of the takeover bid (Reuters).
A takeover offer of 233 Danish crowns per share by a consortium led by Nordic Capital and Permira values the company at about DKK 19 billion, representing a significant premium and strategic endorsement from private-equity investors with board support (Reuters).
Shares plunged about 10% after Bavarian Nordic’s 2025 revenue guidance of DKK 5.7–6.7 billion fell short of the LSEG consensus of DKK 6.42 billion and its EBITDA outlook missed expectations, underscoring investor disappointment and potential cash-flow concerns (Reuters).
Ongoing takeover discussions with Nordic Capital and Permira lack certainty on offer terms, timing, and completion—despite a recent share rally—creating strategic ambiguity that may pressure the stock until a definitive deal materializes (Reuters).
The company flagged that revenue and EBITDA will vary throughout 2025 due to the seasonality of its Travel Health business and the timing of Public Preparedness order deliveries, reducing visibility into quarterly performance and raising the risk of uneven results (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bavarian Nordic A/S stock?
Bavarian Nordic A/S (BAVA) has a market cap of €2.5B as of September 16, 2025.
What is the P/E ratio for Bavarian Nordic A/S stock?
The price to earnings (P/E) ratio for Bavarian Nordic A/S (BAVA) stock is 12.91 as of September 16, 2025.
Does Bavarian Nordic A/S stock pay dividends?
No, Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Bavarian Nordic A/S dividend payment date?
Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Bavarian Nordic A/S?
Bavarian Nordic A/S (BAVA) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.